Nemus THC Pro-Drug Receives Patent in Japan

COSTA MESA, CA--(Marketwired - October 22, 2015) - Nemus Bioscience, Inc. (OTCQB: NMUS) has announced that the pro-drug of tetrahydrocannabinol (THC) in-licensed from the company's research and commercial partner, the University of Mississippi, has been granted a utility patent in Japan. The patent refers to the composition of matter and preparation of delta-9 THC amino acid esters and their methods of use. The lead Nemus compound in development for glaucoma, NB1111, would fall under this patent umbrella.

"Nemus is delighted that this intellectual property has been recognized in Japan," commented Brian Murphy, M.D., M.P.H., who serves as both CEO and Chief Medical Officer of Nemus. "The Japanese therapeutics market is recognized as the world's second largest, behind that of the United States. Pharmaceutical sales from 2013 have been estimated at USD $113 billion and the management at Nemus recognizes the importance of this market in terms of urgent medical need...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.